Search results
Results From The WOW.Com Content Network
The Curative SARS-CoV-2 Assay is a nucleic acid amplification test (NAAT), reverse transcription polymerase chain reaction test (RT-PCR) for COVID-19. The test was designed to be scalable in response to changes in demand, and uses a healthcare worker observed, self-collected oral fluid swab to obtain specimens for testing.
Effectively, SARS manages, administers, and implements the tax regime as designed by the Minister and National Treasury. SARS was established in 1997 by a merger of the customs and inland revenue departments, at the recommendation of the Katz Commission, which had been instituted to review the South African tax system for the post-apartheid era.
On May 25, 2021, an additional test was made available on the LIAISON IQ platform, to detect the COVID-19 antigen in nasal and nasopharyngeal swabs. Both tests use lateral flow technology. On May 21, 2021, Diasorin launched a molecular diagnostic test to easily detect the mutations associated with the most common variants of SARS-CoV-2. [38]
In March 2020, the company announced a rapid diagnostic test for SARS-CoV-2; the U.S. FDA granted an emergency use authorization for the test. [19] The diagnostic is designed to run on any of the (over 23,000) existing Cepheid GeneXpert machines worldwide, with the standard 45 minute detection time. [20]
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. [3]On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic.
In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. [63] In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. [64] In July 2020, the company was processing 165,000 COVID-19 tests per day. [65]
On March 11, 2020, bioMérieux announced the finalization of their real-time PCR SARS-COV-2 R-GENE test. The company also announced the development of a fully automated test based on the BioFire FilmArray technology with the support of the United States Department of Defense. Lastly, bioMérieux launched development on an expanded version of ...
Quidel's "Sofia 2 SARS Antigen FIA" [66] [163] is a lateral flow test that uses monoclonal antibodies to detect the virus's nucleocapsid (N) protein. [164] The result is read out by the company's Sofia 2 device using immunofluorescence. [164] The test is simpler and cheaper but less accurate than nucleic acid tests.